Tags

Type your tag names separated by a space and hit enter

Performance of a molecular viability assay for the diagnosis of Pneumocystis pneumonia in HIV-infected patients.
Diagn Microbiol Infect Dis. 2007 Feb; 57(2):169-76.DM

Abstract

Pneumocystis pneumonia (PCP), caused by infection with Pneumocystis jirovecii, remains an important opportunistic infection in humans. A reverse transcriptase polymerase chain reaction assay has been shown to specifically detect viable P. jirovecii organisms. In the current study, we evaluated this assay on different types of respiratory samples. The assay had a diagnostic sensitivity of 100% and a specificity of 86% when applied to bronchoalveolar lavage samples. The assay's performance declined when applied to less invasive induced sputum and oropharyngeal wash (OPW) samples. The sensitivity, when applied to OPWs, was improved by examining multiple sequential OPW samples and was affected by clinical sampling parameters that could increase or decrease the number of potential organisms in the oropharynx. When used in conjunction with an optimized clinical sampling protocol, this assay may become a useful tool for detecting and monitoring P. jirovecii in minimally invasive clinical samples.

Authors+Show Affiliations

Division of Geographic Medicine, BBRB Box 7, University of Alabama at Birmingham, Birmingham, AL 35294, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17049800

Citation

de Oliveira, Ana, et al. "Performance of a Molecular Viability Assay for the Diagnosis of Pneumocystis Pneumonia in HIV-infected Patients." Diagnostic Microbiology and Infectious Disease, vol. 57, no. 2, 2007, pp. 169-76.
de Oliveira A, Unnasch TR, Crothers K, et al. Performance of a molecular viability assay for the diagnosis of Pneumocystis pneumonia in HIV-infected patients. Diagn Microbiol Infect Dis. 2007;57(2):169-76.
de Oliveira, A., Unnasch, T. R., Crothers, K., Eiser, S., Zucchi, P., Moir, J., Beard, C. B., Lawrence, G. G., & Huang, L. (2007). Performance of a molecular viability assay for the diagnosis of Pneumocystis pneumonia in HIV-infected patients. Diagnostic Microbiology and Infectious Disease, 57(2), 169-76.
de Oliveira A, et al. Performance of a Molecular Viability Assay for the Diagnosis of Pneumocystis Pneumonia in HIV-infected Patients. Diagn Microbiol Infect Dis. 2007;57(2):169-76. PubMed PMID: 17049800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Performance of a molecular viability assay for the diagnosis of Pneumocystis pneumonia in HIV-infected patients. AU - de Oliveira,Ana, AU - Unnasch,Thomas R, AU - Crothers,Kristina, AU - Eiser,Shary, AU - Zucchi,Patrizia, AU - Moir,Jonathan, AU - Beard,Charles B, AU - Lawrence,Gena G, AU - Huang,Laurence, Y1 - 2006/10/17/ PY - 2006/05/15/received PY - 2006/08/14/revised PY - 2006/08/17/accepted PY - 2006/10/20/pubmed PY - 2007/6/22/medline PY - 2006/10/20/entrez SP - 169 EP - 76 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 57 IS - 2 N2 - Pneumocystis pneumonia (PCP), caused by infection with Pneumocystis jirovecii, remains an important opportunistic infection in humans. A reverse transcriptase polymerase chain reaction assay has been shown to specifically detect viable P. jirovecii organisms. In the current study, we evaluated this assay on different types of respiratory samples. The assay had a diagnostic sensitivity of 100% and a specificity of 86% when applied to bronchoalveolar lavage samples. The assay's performance declined when applied to less invasive induced sputum and oropharyngeal wash (OPW) samples. The sensitivity, when applied to OPWs, was improved by examining multiple sequential OPW samples and was affected by clinical sampling parameters that could increase or decrease the number of potential organisms in the oropharynx. When used in conjunction with an optimized clinical sampling protocol, this assay may become a useful tool for detecting and monitoring P. jirovecii in minimally invasive clinical samples. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/17049800/Performance_of_a_molecular_viability_assay_for_the_diagnosis_of_Pneumocystis_pneumonia_in_HIV_infected_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(06)00327-0 DB - PRIME DP - Unbound Medicine ER -